Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

July 09, 2002; 59 (1) Brief Communications

Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma

T. J. Postma, M. Klein, C. C.P. Verstappen, J. E.C. Bromberg, M. Swennen, J. A. Langendijk, M. J.B. Taphoorn, P. Scheltens, B. J. Slotman, H. M. van der Ploeg, N. K. Aaronson, J. J. Heimans
First published July 9, 2002, DOI: https://doi.org/10.1212/WNL.59.1.121
T. J. Postma
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Klein
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. C.P. Verstappen
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. E.C. Bromberg
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Swennen
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. A. Langendijk
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. J.B. Taphoorn
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Scheltens
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. J. Slotman
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. M. van der Ploeg
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. K. Aaronson
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. J. Heimans
From the Departments of Neurology (Drs. Postma, Verstappen, Scheltens, and Heimans), Medical Psychology (Drs. Klein, van der Ploeg, and Aaronson), and Radiation Oncology (Drs. Langendijk and Slotman), Vrije Universiteit Medical Center, Amsterdam; Department of Neurology (Drs. Bromberg, Swennen, and Taphoorn), University Medical Center, Utrecht; Department of Psychosocial Research and Epidemiology (Dr. Aaronson), The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma
T. J. Postma, M. Klein, C. C.P. Verstappen, J. E.C. Bromberg, M. Swennen, J. A. Langendijk, M. J.B. Taphoorn, P. Scheltens, B. J. Slotman, H. M. van der Ploeg, N. K. Aaronson, J. J. Heimans
Neurology Jul 2002, 59 (1) 121-123; DOI: 10.1212/WNL.59.1.121

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
569

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Abnormalities on CT or MRI and neuropsychological performance in patients with low-grade glioma, with (n = 23) or without (n = 16) prior cerebral radiotherapy, were evaluated. Cerebral atrophy was observed in 14 of 23 patients (61%) treated with prior radiotherapy, and in 1 of 16 patients (6%) without prior radiotherapy. White matter abnormalities were observed in six patients, all of whom were treated with prior radiotherapy. These radiologic cerebral abnormalities correlated with cognitive performance.

The timing of radiotherapy in the treatment of patients with low-grade glioma (LGG) is controversial. Some advocate early radiotherapy (RT), whereas others defer RT because the survival benefit of early RT is questionable in this patient population.1

An important argument for delaying cerebral RT is the CNS toxicity this treatment may cause. Radiation-induced white matter changes and cerebral atrophy are well known entities, related to radiation dose, volume, and patient age.2,3⇓ In long-term survivors with high-grade glioma or brain metastases, radiation-induced cognitive deficits have been described.4,5⇓ In our former study of patients with LGG, no differences in cognitive, affective, or psychological status were observed between patients who had been treated with focal RT and those who had not.6 More recently, however, leukoencephalopathy, related to poor memory performance as a long-term side effect, was observed in patients with LGG treated with whole-brain or focal irradiation.7

The exact relationship between radiation-induced cerebral changes and cognitive functioning is not clear.2 The aim of the current study was to test the hypothesis that radiotherapy-induced radiologic cerebral changes, such as atrophy and white matter abnormalities, and cognitive performance are correlated.

Methods.

Recently, a nationwide study was performed in the Netherlands among 195 patients with LGG. In this study, a comprehensive set of neuropsychological and quality of life measurements was incorporated to determine the impact of glioma and its treatment on cognition and quality of life.8 The study was cross-sectional in design, and included patients with LGG without evidence of tumor recurrence for at least 1 year after initial treatment. The current report focuses on all patients with a supratentorial LGG recruited in the study from two of the participating centers (Vrije Universiteit Medical Center, Amsterdam; and University Medical Center, Utrecht) for whom radiologic assessments (CT, MRI, or both) within 6 months of neuropsychological evaluation were available. Data on age, sex, histology, location of tumor, concomitant diseases, previous history, concomitant use of antiepileptic drugs, extent of resection, and RT were collected. CT and MRI scans were evaluated (by T.P., C.V., J.B., M.S.) with emphasis on cerebral atrophy and white matter abnormalities. White matter changes were scored as 0, 1, or 2, depending on the amount, confluence, and spread of these changes in both the anterior or posterior white matter, leading to a score ranging from 0 to 4.9 Scoring was as follows: MRI grade 0: no lesion or only a single one; MRI grade 1: multiple focal lesions; MRI grade 2: multiple confluent lesions scattered throughout the white matter; CT grade 0: no lesions; CT grade 1: white matter lesions restricted to the region adjoining the ventricles; CT grade 2: hypodensities involving the entire region from lateral ventricle to the cortex. The scoring system for cerebral atrophy consisted of a systematic evaluation of 13 different regions to determine sulcal dilatation (frontal, parieto-occipital, and temporal, on both sides) and dilatation of the ventricles (frontal horn, occipital and temporal horns on both sides, third ventricle).10 In these 13 regions, atrophy is qualified as 0 (absent), 1 (mild), 2 (moderate), and 3 (severe), leading to a composite score ranging from 0 to 39. The raters were blinded to the neuropsychological status of the patients and whether patients had received RT. In case of discordance between observers, a single score was obtained after discussion. Abnormalities in the region of the tumor (e.g., postoperative changes) were not taken into account in this analysis.

A battery of standard tests was used to assess cognitive performance. Because of the heterogeneity of both origin and severity of cognitive disturbances in patients with glioma,4,6⇓ the cognitive test battery assessed a wide range of functions, including information processing capacity (Letter-Digit Substitution Test), memory performance (Visual Verbal Learning Test), attention (Stroop Color-Word Test), and graphomotor speed (Concept Shifting Test). The total time required to complete the battery of tests was approximately 60 minutes.

Mann–Whitney U tests for independent samples were used to determine differences between the groups of patients with LGG with (RT+) and without (RT−) RT. To explore the association between cognitive performance and the extent of cerebral atrophy or white matter abnormalities, Spearman’s rho tests were carried out.

Results.

Twenty-three of 39 patients included had received RT. In most of these patients (n = 19), the target volume of RT encompassed the primary tumor site with a 1 to 2 cm margin; in the other four patients, whole brain radiotherapy (WBRT) with a boost to the tumor site was given.

Patient characteristics such as sex, median age at the time of neuropsychological testing, median interval between neuropsychological testing and prior RT (5 years) or initial diagnosis in case no RT had been applied (4 years), level of education, dexterity, history of epilepsy, use of antiepileptic drugs, prior surgery, histology, and localization of the tumor were equally distributed without significant differences between the groups (table 1). None of the patients had a history of hypertension, diabetes mellitus, or recent use of dexamethasone.

View this table:
  • View inline
  • View popup
Table 1.

Low grade glioma patient characteristics

CT was available for 11 patients (10 RT+). MRI was available for 28 patients (13 RT+). Cerebral atrophy was observed in 15 patients (38%). Fourteen of those 15 patients (93%) had been treated with RT (11 patients with focal RT, 3 with WBRT + boost). Atrophy was usually mild to moderate (score range 1 to 17, median 4). Sulcal dilatation occurred in four patients, ventricular enlargement in seven patients, and both sulcal and ventricular enlargement in four patients. These abnormalities were not restricted to the side of the tumor. Ventricular enlargement was pronounced (score 12) in 3 of 4 patients treated with WBRT + boost, and in 2 of 19 patients treated with focal RT.

White matter changes were observed in 6 patients (15%), with scores ranging from 1 to 4 (median 2). All six patients had been treated with RT (three patients with WBRT + boost, three with focal RT). Four of those six patients also had cerebral atrophy.

In table 2, correlations are shown between radiologic abnormalities and cognitive performance. The presence and extent of cerebral atrophy correlated significantly with graphomotor speed, information processing capacity, and memory performance. The existence of white matter abnormalities correlated significantly with attention, information processing capacity, and memory performance. When we excluded the four patients with WBRT, cerebral atrophy correlated with memory performance (p < 0.01), whereas white matter abnormalities correlated with attention (p = 0.04), and with information processing capacity (p = 0.05).

View this table:
  • View inline
  • View popup
Table 2.

Correlations between radiologic abnormalities and cognitive performance

Discussion.

In this study, cerebral atrophy was observed in 14 of 23 patients (61%) treated with prior RT, and in 1 of 16 patients (6%) without prior RT. In patients treated with WBRT + boost, pronounced ventricular enlargement occurred more frequently. The observed radiologic changes due to cerebral RT are in line with the literature.2,3⇓ The relatively low frequency of white matter abnormalities in our cohort may be due to the high proportion of CT in irradiated patients.

Furthermore, modest significant associations were found between the extent of radiologic cerebral abnormalities and cognitive performance. Apparently, not only white matter abnormalities7 but also cerebral atrophy relate to some extent with cognitive performance.

The current study has its limitations. The number of patients in this study was relatively small, which precluded an analysis of the correlation between neuropsychological data and exact tumor location (e.g., frontal vs parietal location), or extent of residual tumor. Furthermore, the large nationwide study will ultimately yield data on the effects of the brain tumor itself and its treatment on cognitive performance.8

Based on our findings, it may be tentatively concluded that long-term cognitive performance and radiation-induced radiologic cerebral abnormalities are correlated in patients with LGG.

Footnotes

  • See also pages 8, 40, and 48

  • Received August 7, 2001.
  • Accepted in final form February 16, 2002.

References

  1. ↵
    Karim ABMF, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult. European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BR04: an interim analysis. Int J Radiation Oncol Biol Phys . 2002; 52: 316–324.
    OpenUrlCrossRefPubMed
  2. ↵
    Corn BW, Yousem DM, Scott CB, et al. White matter changes are correlated significantly with radiation dose. Cancer . 1994; 74: 2828–2835.
    OpenUrlCrossRefPubMed
  3. ↵
    Constine LS, Konski A, Ekholm S, McDonald S, Rubin P. Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiation Oncology Biol Phys . 1988; 15: 319–330.
    OpenUrlCrossRefPubMed
  4. ↵
    Archibald YM, Lunn D, Ruttan LA, et al. Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg . 1994; 80: 247–253.
    OpenUrlCrossRefPubMed
  5. ↵
    DeAngelis LM, Delattre J-Y, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology . 1989; 39: 789–796.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Taphoorn MJB, Klein Schiphorst A, Snoek FJ, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol . 1994; 36: 48–54.
    OpenUrlCrossRefPubMed
  7. ↵
    Surma-aho O, Niemelä M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology . 2001; 56: 1285–1290.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Klein M, Taphoorn MJB, Aaronson NK, van der Ploeg HM, Heimans JJ. Neurosurgery and radiotherapy in the treatment of low-grade astrocytomas and oligodendrogliomas: the cognitive sequelae. Neuro-Oncology . 1999; 1: 318.Abstract.
    OpenUrl
  9. ↵
    van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry . 1990; 53: 1080–1083.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Pasquier F, Leys D, Weerts JGE, Mounier–Vehier F, Barkhof F, Scheltens PH. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol . 1996; 36: 268–272.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • Neurocognitive sequelae of cancer treatment

Topics Discussed

  • All Oncology
  • All Cognitive Disorders/Dementia
  • Primary brain tumor
  • Radiation therapy-tumor

Alert Me

  • Alert me when eletters are published
Neurology: 100 (12)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise